Business
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
TOKYO & HYOGO, Japan, September 29, 2025--JCR and MEDIPAL announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446 for MPS IIIB.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/7a4252f4fb0eba7a3f9601df373ccd6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8sx6jSJjEIbqHFaxea1BMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7a4252f4fb0eba7a3f9601df373ccd6b","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/eebd3a4bc54e76a98b7b9b1b3992a8ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AOrYEzzZ1eaj3Chrfmg7kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eebd3a4bc54e76a98b7b9b1b3992a8ce","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4L5YAYvDzK_RZOOaKdt3ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/eebd3a4bc54e76a98b7b9b1b3992a8ce","width":1024,"height":512}}},{"type":"text","content":"TOKYO & HYOGO, Japan, September 29, 2025--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) today announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B).","length":400,"tagName":"p"},{"type":"text","content":"JR-446 was granted orphan drug designation for the treatment of MPS IIIB by the U.S. Food and Drug Administration (FDA) in April 2025,1 and by the European Commission (EC) in June 2025.2","length":186,"tagName":"p"},{"type":"text","content":"MPS IIIB affects an estimated 500 to 1,000 individuals worldwide,3 causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR’s proprietary J-Brain Cargo® technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/...